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Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of immunocom-
promised humans, caused by the opportunistic fungal pathogen Aspergillus fumigatus.
Inadequacies in current diagnostic procedures mean that early diagnosis of the disease,
critical to patient survival, remains a major clinical challenge, and is leading to the empiric use
of antifungal drugs and emergence of azole resistance. A non-invasive procedure that allows
both unambiguous detection of IPA and its response to azole treatment is therefore needed.
Here, we show that a humanised Aspergillus-specific monoclonal antibody, dual labelled with
a radionuclide and fluorophore, can be used in immunoPET/MRI in vivo in a neutropenic
mouse model and 3D light sheet fluorescence microscopy ex vivo in the infected mouse lungs
to quantify early A. fumigatus lung infections and to monitor the efficacy of azole therapy. Our
antibody-guided approach reveals that early drug intervention is critical to prevent complete
invasion of the lungs by the fungus, and demonstrates the power of molecular imaging as a
non-invasive procedure for tracking IPA in vivo.
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A spergillus fumigatus is an abundant environmental mold,with air-borne spores that are frequently inhaled. Thefungus is an opportunistic pathogen, and while the
immune system of healthy individuals is highly effective at
eliminating infective spores from the lung, patients with impaired
immunity, especially those with hematological malignancies,
prolonged neutropenia, or recipients of hematopoietic stem cell
or solid organ transplants, are at elevated risk of developing
invasive pulmonary aspergillosis (IPA), a rapidly progressive and
often fatal lung disease caused by germinated spores of the
pathogen. The disease is also increasingly reported in patients
with underlying respiratory diseases such as severe asthma and
COPD, and as co-infections in patients with severe influenza and
with Covid-19 coronavirus1–3, regardless of their immune system
status4,5. The high mortality rate of IPA6 is exacerbated by the
lack of rapid, specific and sensitive diagnostic tests. Since the
symptoms of the disease (fever and chills, haemoptysis, shortness
of breath, chest pain, headaches) are nonspecific, diagnosis relies
on culture of the pathogen from invasive biopsy7, or detection of
biomarkers in serum or in bronchoalveolar lavage fluid (BALf)
recovered during invasive bronchoscopy8. Attempts have been
made to improve noninvasive diagnosis using computed tomo-
graphy (CT)8 or magnetic resonance imaging (MRI)9 of the chest,
but radiological indicators of infection are not pathognomonic for
IPA. Despite this, a radiological abnormality in a chest-CT is used
in many centers as a trigger for initiating antifungal drug treat-
ment in a febrile patient unresponsive to antibiotics10. Inap-
propriate or delayed treatment of IPA, driven by imprecise
diagnostic procedures, negatively impacts on patient morbidity
and mortality, and is contributing to the emergence of azole
resistance in clinical strains of A. fumigatus11,12. Therefore,
improvements in IPA diagnosis are needed that allow non-
invasive detection of lung infection in vivo, and enable mon-
itoring of disease responsiveness to antifungal drug treatments.
The use of targeted contrast agents in molecular imaging pro-
cedures such as positron emission tomography (PET) or single
photon emission computed tomography (SPECT) holds enormous
promise in addressing this unmet need13,14. While PET has pro-
ven its imaging capabilities, leading to its widespread use in
oncology, only very few studies have tried to capitalize on its
potentially high sensitivity and selectivity for infectious disease
diagnosis beyond [18F]FDG. For invasive mycoses, radiolabeled
antifungal drugs15 or fungal siderophores16,17 have been attemp-
ted, with mixed preclinical success, but their translation to the
clinic appears problematic due to their lack of specificity. This
limitation is overcome by the use of radiolabeled monoclonal
antibodies, whose specificity allows targeted detection of indivi-
dual pathogens when applied in immunoPET. Recently, we have
focused on an Aspergillus-specific mAb, JF518, which binds to an
antigen expressed on the surface of actively growing hyphae of A.
fumigatus. While initial investigations using 64Cu-radiolabeled
murine JF5 showed promising results for in vivo imaging of IPA
in a mouse model of the disease19, further improvements in JF5-
guided PET/MR imaging were met through its humanization20,
enabling translation of the technology to the clinical setting.
An important but unexplored aspect of molecular imaging is its
use as a treatment monitoring tool for invasive fungal diseases.
While attempts have been made to use circulating biomarkers to
monitor responsiveness of IPA to antifungal treatment21, it is
well-documented that the sensitivities of diagnostic biomarker
tests for the disease, such as the Aspergillus galactomannan (GM)
ELISA and fungal β-D-glucan assay, are markedly influenced by
mold-active azoles such as voriconazole (VCZ), both in model
systems and in humans22,23. Furthermore, there is no data cur-
rently available on the relationship between fungal biomass in the
lung and amounts of circulating biomarkers in serum or BALf,
and so it is not possible to determine unequivocally whether lung
infection has been resolved without a visual appraisal using
nonspecific chest-CT.
A key step to using immunoPET/MRI as a treatment mon-
itoring tool is to establish whether it is sufficiently accurate to
allow changes in Aspergillus load in the lung to be quantified in
response to antifungal drug treatment. To this end, we set out
here to (1) establish whether accumulation in the lung of the
humanized JF5 (hJF5) radiotracer during A. fumigatus infection
of neutropenic mice is directly related to fungal load, and (2)
whether changes in the fungal load in the lung coincident with
VCZ treatment can be monitored quantitatively in vivo. To
achieve these goals, we developed a dual-labeled hJF5 variant
bearing both a radionuclide and a fluorophore, [64Cu]Cu-
NODAGA-hJF5-DyLight650 (hereafter 64Cu-hJF5-DyLight650),
which allowed us to co-localize and to co-quantify the pathogen
and tracer in the lung both in vivo using broad resolution
immunoPET/MRI, and ex vivo using high-resolution 3D light
sheet fluorescence microscopy. Using this approach, we show that
immunoPET/MRI can be used to monitor disease progression
during treatment with an azole drug, and that early intervention
with the drug is critical to preventing A. fumigatus infection.
Results
Characterization of the dual-labeled 64Cu-hJF5-DyLight650
antibody. The elution profile of the double-conjugated and
radiolabeled antibody showed a single peak corresponding to the
molecular weight of the antibody, with no detectable aggregates
and only a small (<5%) dimer peak (Supplementary Fig. 1). To
exclude detrimental effects of the chelator and fluorophore con-
jugation to antigen binding, the reactivity of the double-
conjugated antibody was determined by ELISA using serial
dilutions of the respective antibodies (Supplementary Fig. 2). We
found only slightly reduced antigen binding of the antibody after
single (NODAGA) and double (NODAGA and DyLight) con-
jugations, compared to the unconjugated antibody. Fitting of the
binding curves revealed apparent Kd values of 67 pM (unmodi-
fied antibody), 59 pM (NODAGA-conjugated), and 112 pM
(double-conjugated).
Light sheet fluorescence microscopy of A. fumigatus in healthy
and neutropenic mice. To visualize the proliferation of A.
fumigatustdTomato in healthy and neutropenic animals, their lungs
were removed 30 min, 6, 24, and 48 h postinfection. Following
fixation and clearing, the lungs were imaged using Light Sheet
Fluorescence Microscopy with the fungus being detectable via the
endogenous tdTomato fluorescence signal (Fig. 1a). This revealed
that in both immunosuppressed (neutropenic) and immuno-
competent animals, there was patchy distribution of the pathogen
30 min after administration of the spore inoculum (Fig. 1b).
Infestation of the lungs of neutropenic mice had occurred by 6 h
p.i., with further proliferation of the pathogen thereafter until
termination of the experiment. In comparison, healthy animals
receiving the same spore inoculum showed a markedly reduced
proliferation of the pathogen during the first 6 h postinfection,
and a complete cessation by 48 h (Fig. 1b). High-resolution
multiphoton microscopy of the same samples showed that the
neutrophil depletion permitted substantial hyphal outgrowth by
24 h which was further increased by 48 h. In contrast, the pre-
sence of neutrophils completely blocked hyphal development, and
led to total recovery of previously infected lung tissues, such that
by 48 h it was morphologically indistinguishable from the non-
infected lung (Fig. 1c).
Quantification showed that while the initial loads of A. fumigatus
were comparable at the earliest time point (30min p.i.), differences
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in loads between healthy and neutropenic mice were evident as
early as 6 h p.i., and continued to rise over the period of observation
(Fig. 1d). Hence, a functional neutrophil response controls fungal
spread within the first hours of infection and effectively suppresses
hyphal development.
In vivo immunoPET/MR of A. fumigatus infection and treat-
ment monitoring. In previous studies, we showed the potential of
the murine mAb JF5 and its humanized counterpart hJF519,20 to
detect A. fumigatus lung infection in vivo using PET/MR. To
determine whether this approach could be applied to treatment
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monitoring, we investigated the growth of A. fumigatustdTomato in
the lungs of healthy or neutrophil-depleted mice in response to
treatment with VCZ, a triazole drug used in humans for primary
therapy of IPA24. We first determined the VCZ susceptibility of
our A. fumigatus strains (the wild-type strain ATCC 46645 and
the genetically modified derivative A. fumigatustdTomato). Mini-
mum inhibitory concentration (MIC) determination for VCZ by
visual reading, as suggested in the EUCAST guidelines25, resulted
in 0.5 µg/ml for ATCC 46645 as well as for A. fumigatustdTomato
strain (Supplementary Fig. 3 and Supplementary Table 1), similar
to published data25. To corroborate these results with a quanti-
tative reading method we analyzed the 96-well plates spectro-
photometrically following the suggestion of Meletiadis et al.26.
The results of the spectrophotometrical analysis yielded a VCZ
MIC of 0.5 µg/ml for ATCC 46645 and of 0.25 µg/ml for strain
A. fumigatustdTomato (Supplementary Fig. 4 and Supplementary
Table 2). These confirmed our previous findings using visual
appraisals, and are consistent with the MIC range published in
the works of Lass-Flörl and Meletiadis et al. In in vivo experi-
ments, we first tested i.v. administration of VCZ 24 h postinfec-
tion and tracer injection (Fig. 2a), the time period corresponding
to widespread colonization of the neutropenic lung (Fig. 1b).
Images acquired 24 and 48 h after 64Cu-hJF5 and inoculum
injection, showed no differences in the qualitative distribution of
the radiotracer in the lungs of animals with VCZ treatment and
those without (Fig. 2b). Indeed, significant accumulation was seen
in the lungs of both groups of animals due to specific binding of
the antibody tracer to its hyphal-bound antigen, and in the spleen
due to soluble circulating antigen, a phenomenon reported
previously19,20. As expected, a 64Cu signal could also been seen in
the heart, indicating prolonged circulation of the radiotracer.
Quantification of the in vivo 64Cu PET signal in the lungs,
expressed as %ID/cc (Fig. 2c), confirmed the distributions seen
qualitatively (Fig. 2b). No significant differences in tracer uptake
in the lungs were found between VCZ-treated and non-treated
animals at 24 h (10.0 ± 2.0%ID/cc and 9.9 ± 1.7%ID/cc, respec-
tively) and 48 h (11.1 ± 1.7%ID/cc and 12.9 ± 2.7%ID/cc, respec-
tively). At 48 h, a significant increase in lung uptake of 64Cu-hJF5
could be seen in both groups compared to the control animals
(6.5 ± 1.7%ID/cc) and, while the lung PET signal remained stable
through time in control animals, the signal in infected animals
increased significantly over the 48 h period, reaching a contrast
ratio of ~2. Ex vivo biodistribution analysis of the tracer in dif-
ferent organs at 48 h (Fig. 2d) after perfusion by 0.4% PFA
showed no significant differences in lung uptake between VCZ-
treated and non-treated animals (38.4 ± 8.9%ID/g and 41 ± 18%
ID/g, respectively), but with both significantly greater compared
to control (uninfected) animals (3.9 ± 1.2%ID/g). Although no
differences could be seen in heart or muscle uptake between
groups, differences in the accumulation of 64Cu-hJF5 could be
seen in the spleens of control and infected animals, with infected
animals displaying an approximate twofold increase in uptake
regardless of VCZ treatment. The circulating blood levels of the
64Cu-hJF5 tracer, obtained from blood sampling performed
directly before animal perfusion, were similar in the infected
cohorts (31.9 ± 5.8%ID/cc and 36.4 ± 2.8%ID/cc in untreated and
azole-treated groups, respectively), which was higher than in the
control group (19.7 ± 2.6%ID/cc) indicating the long half-life of
the full-length IgG in the bloodstream, but also possibly due to
binding of the radiolabeled antibody to circulating antigen. Col-
lectively, these data show that treatment with VCZ following
establishment of lung infection by A. fumigatus, has no mea-
surable effect on progression of disease in the neutropenic lung
within the timeframe of the experiment.
Dual-label in vivo immunoPET and ex vivo LSFM. The lack of
effect of VCZ led us to investigate whether the macroscopic
resolution of PET/MR was insufficient to discriminate subtle
differences in fungal burden consequent with antifungal treat-
ment. We therefore set out to investigate the correlation between
tracer accumulation and fungal burden in the lung using a
combined PET/MR and LSFM imaging approach. To this end, we
developed a dual-labeled derivative of hJF5, with 64Cu as the
radioactive PET reporter, and DyLight650 as a fluorescent
reporter for optical imaging. After infecting neutropenic mice
with A. fumigatustdTomato and immediately injecting 64Cu-hJF5-
DyLight650, we determined whether VCZ administered 24 h after
infection had an effect on the spatial distribution of the antibody
48 h after infection, and its co-localization with the fungus in
infection sites at a macroscopic and microscopic level (Fig. 3a).
Imaging the same lungs with both in vivo immunoPET/MR and
ex vivo LSFM (Fig. 3b, c) revealed, qualitatively, complete overlap
between fungal growth (depicted by red tdTomato fluorescence)
(Fig. 3c), hJF5 labeling of hyphal antigen via the green
DyLight650 fluorophore (Fig. 3c), and macroscopic distribution
in vivo via the radionuclide 64Cu in immunoPET/MR (Fig. 3b).
Confocal microscopy of the 64Cu-hJF5-DyLight650 molecule and
tdTomato fluorescence further showed co-localization of fungal
foci and the antibody at the microscopic level (Fig. 3d).
In vivo and ex vivo volumetric quantification of fungal inva-
sion. In order to quantify fungal load in the lungs in vivo, we
investigated how thresholding of the PET signal at different
radiotracer accumulation values might enable accurate measure-
ments of the volume occupied by the pathogen to be made. The
ratio of the infection volume, as measured in PET, to the overall
lung volume measured in MRI is shown in Fig. 4a. While a low
threshold of 5%ID/cc, under the average %ID/cc in healthy ani-
mals, provided a significant difference between healthy controls
and diseased animals, it nevertheless gave a strong false negative
result, with ~50% of lungs supposedly infected in control animals.
The variability was also high, since the threshold value was close to
the background level. In contrast, a threshold of 10%ID/cc,
selected to be significantly above the average PET tracer accu-
mulation of a healthy lung at 48 h (6.5 ± 1.7%ID/cc), showed a
significant difference between control and infected animals (3.2 ±
4.5% compared to 61 ± 4.5%; p < 0.005). However, VCZ-treated
animals did not show any difference when compared to non-
Fig. 1 Development of invasive pulmonary aspergillosis under healthy and immunosuppressed conditions. a Schematic experimental workflow.
Neutropenic groups were depleted with Gr-1 antibody 18 h prior to intratracheal (i.t.) inoculation with Aspergillus fumigatustdTomato conidia. Lungs were
subsequently removed at different time postinfection (p.i.), cleared and imaged using light sheet fluorescence microscopy (LSFM). b Lung tissue (gray) and
fungal biomass (red) is depicted for time points 0, 0.5, 6, 24, and 48 h during disease progression. Images were constructed using surface tool from Imaris.
Scale bar= 1 mm. c Magnified two-photon microscopy images of the same lungs as in b, with lung tissue (gray), and fungal biomass (red). Scale bar= 50
µm. d Plot of fungal load per whole lung lobe for the different treatments over time. Sham-depleted, Aspergillus fumigatus (A.f.) infected group (PBS-A.f.,
gray circle, n= 2 per time point), Gr-1 neutrophil-depleted and infected group (Gr1-A.f., red triangles, n= 3 per time point), isotype-depleted and infected
group (Iso-A.f., orange squares, n= 1 per time point). Results are plotted as individual values with average and standard deviation where applicable.
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treated animals, with an infected volume of 54 ± 8%. A further
increase in threshold volume to 15%ID/cc, selected to match the
maximal PET signal obtained from healthy lung tissue in vivo
(14.3 ± 1.6%ID/cc on average) provided an infected volume of 0%
for control animals with no difference between non-treated and
treated infected animals (22 ± 5% and 21 ± 10%, respectively). An
even higher threshold of 20%ID/cc provided negligible infection
volumes of <5% in infected animals but did not yield significant
differences between groups. In addition, we performed a receiver
operating characteristic analysis (Supplementary Fig. 5). This
showed that 10 and 15%ID/cc were optimal thresholding values
allowing differentiation between healthy and infected animals with
an area under curve (AUC) of 1, whereas the threshold values 5
and 20%ID/cc showed an AUC under 0.9. A similar thresholding
approach was applied to LSFM images (Fig. 4b), comparing the
volumes occupied by A. fumigatustdTomato. While control animals
did not present any fluorescent signal, similar values for volume
occupancy by the pathogen and by the 64Cu-hJF5-DyLight650
tracer were found in infected animals, and in VCZ-treated and
non-treated infected animals, with ~20% of the lung displaying
fluorescence signals (and hence active infection). Co-localization
of A. fumigatus and hJF5, as measured in LSFM, yielded ~75%
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correlation in both treated and non-treated groups (Fig. 4c), which
was further supported by good correlation between the volume
occupied by A. fumigatus in the diseased lung and hJF5-
DyLight650 accumulation, regardless of VCZ treatment
(Fig. 4d). This indicated that DyLight-hJF5 faithfully reports A.
fumigatus invasion in the organ. When the in vivo immunoPET/
MRI and ex vivo LSFM data were combined with a 15%ID/cc
threshold for determination of disease volume (obtained by
thresholding based on maximum signal intensity in healthy
lungs), correlation between immunoPET/MR and LSFM volu-
metric findings per animal (Fig. 4e) showed a linear correlation
(r2= 0.8978 and a slope of 0.87 ± 0.17), which was not the case
with a threshold of 10% (r2= 0.1832). Hence, dual-label imaging
with an hJF5-targeted strategy allows precise determination of the
extent of fungal loading at a macroscopic and microscopic level.
Early onset therapy is critical for infection control. To treat IPA
successfully, it is essential to discover lung infection as early as
possible during disease progression, so as to allow timely treatment
with mold-active drugs. To compare the effectiveness of early- and
late-stage treatment on disease progression, we evaluated animals
treated with VCZ at 3 and 24 h postinfection using immunoPET/
MR. We had already established using LSFM (Fig. 1) that by 6 h
postinfection the pathogen had begun to invade the entire lung,
albeit at a low level, while widespread establishment of the pathogen
had occurred by 24 h. We therefore chose the time points 3 and 24
h postinfection as the points at which to administer VCZ, so that we
could then determine the effectiveness of early and late antifungal
treatment start on disease progression using immunoPET/MR
(Fig. 5a). At 24 h postinfection, immunoPET/MR images of disease
progression under the two different VCZ treatment regimens (3 h
+ 24 h (early/late-stage) or 24 h only (late-stage)) showed minimal
differences in pathogen establishment (Fig. 5b). This was confirmed
by the quantitative in vivo PET data at 24 h postinfection, which
showed no significant difference in tracer uptake for the control
group (infected but untreated mice) (9.8 ± 1.6%ID/cc), mice treated
with VCZ at 24 h (9.5 ± 1.5%ID/cc), and mice treated with VCZ at
3 and 24 h postinfection (8.3 ± 0.6%ID/cc) (Fig. 5c). However, 48 h
after infection, qualitative differences in 64Cu-hJF5 accumulation in
infected animals under late- or early/late-stage treatment were
pronounced, with the early/late-stage treated animals showing very
limited uptake of tracer in the lungs, similar to that seen in non-
infected animals (Figs. 3b and 5b). In contrast, there was extensive
uptake of the tracer in animals receiving late-stage treatment,
similar to that seen in infected, untreated animals (Figs. 3b and 5b).
The quantitative in vivo PET data acquired at 48 h, showed that
animals receiving late-stage treatment had slightly increased uptake
of the tracer compared to levels at 24 h postinfection (11.9 ± 2.2%
ID/cc, Fig. 5c), while animals receiving the early/late-stage treat-
ment displayed significantly (p < 0.005) reduced accumulation
(7.3 ± 0.5%ID/cc) compared to the untreated animals, and those
receiving late-stage VCZ treatment. Using the volumetric approach
described above, with a threshold of 10%ID/cc, significant differ-
ences (p < 0.005) were already apparent at 24 h postinfection
between animals receiving late-stage vs. early/late-stage VCZ
treatment (40 ± 14% and 22 ± 6%, respectively, Fig. 5d) which was
not the case when using a 15%ID/cc threshold. At 48 h postinfec-
tion, the differences in tracer uptake between the two groups was
even more pronounced (61 ± 14% for animals receiving late-stage
VCZ, and 11 ± 4% for animals receiving early/late-stage VCZ
treatment). Using a 10%ID/cc threshold, a significant difference
between animals receiving early/late-stage treatment and the ani-
mals receiving late-stage or no treatment was found although with
high volume occupation values (11 ± 4%ID/cc vs. 61 ± 14 and 58 ±
12%ID/cc, respectively, p < 0.0001). When a 15%ID/cc threshold
was applied to the PET data as in the experimental results presented
in Fig. 4d, e, no positive (infected) volume was exhibited in animals
receiving early/late-stage treatment, while the animals receiving
late-stage treatment displayed a 25 ± 17% infected lung volume
(Fig. 5c). Ex vivo biodistribution data obtained after perfusion of the
animals (Supplementary Fig. 6) were in accordance with the in vivo
findings. They showed a significantly reduced lung accumulation of
64Cu-hJF5 in animals receiving early/late-stage VCZ treatment
compared to the late-stage animals (12 ± 6%ID/g vs. 35 ± 14%ID/g,
respectively, p < 0.001). Liver accumulation showed similar trends,
with 6.9 ± 2.6%ID/g for early/late-stage VCZ-treated animals, and
20 ± 13%ID/g for late-stage treated animals (p < 0.05). While no
other organs showed measurable differences in the accumulation
and retention of 64Cu-hJF5 across the two treatment groups, ani-
mals receiving early/late-stage VCZ treatment displayed an elevated,
albeit non-significant, amount of blood pool tracer. In addition, we
have performed hematoxylin and eosin (H&E) stain as well as
Grocott methenamine silver stain on lung samples to observe the
tissue damage and extent of the fungal invasion (Supplementary
Fig. 7). The lungs of animals infected with A. fumigatus but not
treated showed massive central bronchial infiltration, multiple large
granulomas containing hyphae and spores, cavitations, necrosis,
and destruction of the respiratory epithelium. Lungs receiving late
treatment showed severe damage, with multiple and large Asper-
gillus granulomas containing numerous and large hyphae. Asper-
gillus spores were detected throughout the respiratory parenchyma.
We observed large necrotic areas around the bronchi and severe
destruction of the respiratory epithelium. Angioinvasion was also
detected, with necrosis of the surrounding tissue. The lungs of mice
receiving early treatment showed multiple small bronchio-centric
inflammatory infiltrates with no significant damage of the respira-
tory epithelium. Few and small Aspergillus granulomas were iden-
tified, which contained exclusively spores. No hyphae were detected.
The lungs of the control group (PBS instilled) showed normal
histology, without pathological alterations.
Fig. 2 ImmuoPET/MR imaging of invasive pulmonary aspergillosis in response to voriconazole (VCZ) treatment. a Experimental workflow depicting
neutrophil depletion, Aspergillus fumigatus (A.f.) infection, tracer injection, voriconazole administration (VCZ) and in vivo imaging. b ImmunoPET/MR
images of PBS-deposited animals (Control, left column, n= 4), A. fumigatus-infected animals without VCZ treatment (A. fumigatus, middle column, n= 4),
and with late-stage VCZ treatment (A.f. VCZ (24 h), right column, n= 3). Images acquired 24 h after inoculation (p.i.) are presented in the top row, the
bottom row are images acquired 48 h p.i.. MIP is a Maximum Intensity Projection of the PET image; MRI is a T2-weighted MRI single slice MRI image;
Fusion is a single slice PET image overlaid on the corresponding MRI slice. Magnification of the fusion image in the lung area is displayed below.
c Quantification of 64Cu-hJF5 accumulation in the lung tissue at 24 h (top) and 48 h (bottom) after radiotracer injection in control (Ctrl), infected
(A. fumigatus) and voriconazole treated animals (A.f., VCZ (24 h)). 48 h p.i.: Ctrl vs. A. fumigatus, p= 0.0152; Ctrl vs. A.f., VCZ (24 h), p= 0.0033. d Ex vivo
Biodistribution data of 64Cu-hJF5 in major organs 48 h after radiotracer injection obtained after perfusion of the animal by 0.4% PFA. Blood: Ctrl vs.
A. fumigatus, p= 0.0032; Ctrl vs. A.f., VCZ (24 h), p= 0.0002. Lungs: Ctrl vs. A. fumigatus, p < 0.0001; Ctrl vs. A.f., VCZ (24 h), p < 0.0001. Spleen: Ctrl vs.
A. fumigatus, p= 0.0005; Ctrl vs. A.f., VCZ (24 h), p= 0.0004. Results are plotted as individual values with average and standard deviation and are
expressed as percent injected dose per cubic centimeter (%ID/cc) for PET and injected dose per gram (ID/g) for Biodistribution. p values were generated
using one way ANOVA (c) or two way ANOVA (d) with Tukey’s multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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Discussion
Early and accurate diagnosis and therapy monitoring of IPA
remains a significant clinical challenge due to the paucity of tests
that allow specific and sensitive detection of the disease12. The
recent introductions of a novel CE-marked lateral-flow device27,28
and a CE-marked ELISA test29 that both use monoclonal
antibody JF5 to detect a biomarker of Aspergillus infection have
improved the speed and accuracy of IPA diagnosis, com-
plementing the predicate galactomannan-ELISA test. Despite
improved availability of biomarker tests over recent years, and
significant efforts by the research community to develop non-
invasive urine tests30,31, diagnosis of IPA can be delayed for days,
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Fig. 3 Impact of antifungal treatment measured with PET/MRI and LSFM using dual-labeled 64Cu-hJF5-DyLight650. a Experimental workflow depicting
Aspergillus fumigatus (A.f.) infection, tracer injection, voriconazole administration (VCZ) and imaging using immunoPET/MR and LSFM. b ImmunoPET/MR
images of PBS-deposited animals (Control, left, n= 2), A. fumigatus-infected animals without treatment (A. fumigatus, middle, n= 2) and animals with
voriconazole treatment 24 h after inoculation (A.f. VCZ (24 h), right, n= 3). Images were acquired 48 h postinoculation (p.i.). MIP is a maximum intensity
projection of the PET image; MRI is a T2-weighted MRI single slice MRI image; Fusion is a single slice PET image overlaid on the corresponding MRI slice.
A close-up of the fusion image in the lung area is displayed below. PET data are presented as percent injected dose per cubic centimeter (%ID/cc).
c Detection of 64Cu-hJF5-DyLight650 with LSFM. Surface view of lungs from same animals as in b imaged with LSFM, and with magnified detail shown
below. Lung tissue (gray), A. fumigatus (red) and 64Cu-hJF5-DyLight650 signal (green). Scale bar first row= 1.5 mm, and second row= 300 µm. d High-
resolution confocal images of same lungs as in b. Scale bar= 50 µm.
Fig. 4 Quantification and volumetric analysis of immunoPET and LSFM. a Ratio of infected lung volume as measured by immunoPET to total lung volume
measured via MRI as a function of 64Cu-hJF5-DyLight650 accumulation threshold in percent injected dose per volume (%ID/cc) at 48 h postinoculation in
PBS-deposited animals (Control, left, n= 2), A. fumigatus-infected animals without treatment (A. fumigatus, middle, n= 2) and animals with voriconazole
treatment 24 h after inoculation (A.f. VCZ (24 h), right, n= 3). 5%: Ctrl vs. A.f., VCZ (24 h), p= 0.0062. 10%: Ctrl vs. A.f., VCZ (24 h), p= 0.0013.
b Volumetric ratio of A. fumigatus or 64Cu-hJF5-DyLight650 in the lung as measured by LSFM for each group. c Quantification of the co-localization of
64Cu-hJF5-DyLight650 and A. fumigatustdTomato measured by LSFM in untreated (A. fumigatus, red) and treated (A.f., VCZ (24 h)). d Correlation of A.
fumigatus invasion and 64Cu-hJF5-DyLight650 distribution in the lungs of A. fumigatus-infected animals untreated (A. fumigatus, red) and VCZ treated 24 h
after infection (A.f., VCZ (24 h) as measured by LSFM. e Correlation of 64Cu-hJF5-DyLight650 volumetric distribution in the lungs of A. fumigatus-infected
animals untreated (A. fumigatus, red) and VCZ treated 24 h after infection (A.f., VCZ (24 h) as measured in LSFM and PET using the 15%ID/cc threshold. r2
represents Pearson’s correlation coefficient. Results are plotted as individual values with average and standard deviation. p values were generated using
two way ANOVA with Tukey’s multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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weeks or even months, due to outsourcing of testing to cen-
tralized facilities. Delays in test turnaround, and the need for
timely treatment of febrile patients unresponsive to antibiotics,
leads to the empiric use of antifungal drugs, and limits the use of
biomarker tests as tools to monitor treatment efficacies. At pre-
sent, no non-invasive diagnostic procedure for IPA exists that
provides sufficient specificity and sensitivity to allow for the
quantitative detection of small amounts of fungus in situ, early
diagnosis of Aspergillus infections in vivo, and response of the
pathogen to antifungal drug treatment. To this end, the use of
nuclear medicine techniques such as SPECT and PET imaging
seem ideal, provided suitably specific radiotracers can be
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21965-z ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1707 | https://doi.org/10.1038/s41467-021-21965-z | www.nature.com/naturecommunications 9
developed that enable high affinity and selectivity for IPA. While
recent studies suggest that [18F]FDG-PET/CT might help dis-
criminate between active and residual fungal lesions to support
decisions for safely stopping antifungal treatments32, we have
shown that the metabolic tracer [18F]FDG is not specific for IPA,
and is unable to discriminate between Aspergillus infections,
bacterial infections, and inflammatory processes of the lung19.
Alternative strategies for imaging IPA are therefore needed. The
three main alternatives investigated to date are (1) the use of
radiolabeled antifungal drugs, which show poor ability to detect
A. fumigatus infections, and to differentiate these from infections
by other fungal pathogens33,34; (2) the use of radiolabeled
siderophores30,35,36 which, while demonstrating significant
potential in animals models of disease, may lack sufficient spe-
cificity, and show reduced sensitivity in patients with iron over-
load (typically those at high risk of developing IPA including
heavily transfused AML patients, neutropenic patients, liver and
allogeneic HSCT recipients, and those receiving chemotherapy);13
(3) the use of an Aspergillus-specific mAb, JF5, which allows
highly specific and sensitive detection of A. fumigatus lung
infections in vivo13,19,20, and which has been humanized, via
CDR grafting into a human IgG1 framework, for use as a diag-
nostic tracer in humans20. In parallel, optical detection of A.
fumigatus has been shown in a fungal keratitis model using
fluorescent liposomes, achieving rapid and sensitive diagnosis,
although with an imaging depth too limited for lung imaging37.
In this study, we extend our initial work to examine whether
and how the hJF5 antibody can be used for early diagnosis and
therapy monitoring of IPA. By coupling the antibody to the
radionuclide 64Cu and the fluorophore DyLight 650, we have
gained insight into the progression of A. fumigatus lung infec-
tions in vivo, and the response of infections to early- and late-
stage treatment with the antifungal drug VCZ. Using light sheet
fluorescence microscopy (LSFM), with a mesoscopic sample size
similar to whole animal immunoPET, we were able to quantify, in
3D, uptake of the antibody tracer and development of a geneti-
cally modified strain of the pathogen (A. fumigatustdTomato), in
parallel, in situ. We were therefore able to visualize growth of the
fungus under different conditions in the intact lung both in vivo
and ex vivo, including the role of the neutropenic environment on
pathogen development, and the timing of therapy on disease
progression. This demonstrates the utility of immunoPET as a
nondestructive and noninvasive disease-monitoring tool to
observe the in vivo response of A. fumigatus to antifungal drug
treatment. Previous attempts to study the consequences of anti-
fungal therapy on disease progression have relied on destructive,
invasive, or semi-invasive procedures including histopathological
examination of diseased lung tissues22,38, culture of invasive BALf
samples for estimates of fungal load7, and circulating biomarkers
as proxies of disease burden22,38–40. It is important to mention
that, while our efforts and model were based on the Aspergillus
fumigatus species, the JF5 antibody recognizes and binds to all
Aspergillus species and thus still holds potential in parts of the
world where A. flavus or A. terreus can be the most common
cause of IPA18. In addition, we have focused on the lung pre-
sentation of the disease. While rare, cerebral aspergillosis can also
occur, especially in patients treated with ibrutinib. Here, our
chosen antibody-based approach might be limited as it would
require breakdown of the blood brain barrier (BBB) to allow for
radiolabeled antibody accumulation at the site of infection.
However, A. fumigatus metabolites such as gliotoxins41 have been
shown to impair BBB integrity.
Neutrophils play critical roles in host defence to fungal
infections42. In our neutropenic mouse model of IPA, neutrophil
deficiency, more specifically loss of Gr-1+ cells, resulted in
infection of the entire lung volume within a matter of hours of
challenge with spore inoculum, whereas, in the presence of
neutrophils, the pathogen was rapidly controlled. This demon-
strates further the critical role of Gr-1+ neutrophils in preventing
infectious pathogens43, and provides an additional, and highly
effective, means of depleting neutrophils, to those used by Amich
and co-workers in LSFM of A. fumigatus lung infections44. Sur-
prisingly, in healthy animals, neutrophil-mediated control of lung
infection took longer than expected, as invasion was apparent in
LSFM 6 h after initial deposition of A. fumigatus spores. However,
the spore concentrations used in our investigations were super-
ficially high in order to obtain a complete and rapid invasion of
the lung, and were several orders of magnitude higher than the
daily estimated inhalation of A. fumigatus spores in real-life45.
Nevertheless, the timing of the different stages of lung infection
(conidial germination, hyphal proliferation, and invasive of the
contiguous lung) are similar to those reported in other neu-
tropenic models of IPA22,38.
In order to determine the effectiveness of our molecular ima-
ging approach as a means of monitoring the in vivo response of
invasive lung infection to antifungal treatment, we administered
the azole drug VCZ at early (3 h) and late (24 h) time points
postinoculation, and then quantified spatio-temporal changes in
pathogen load using immunoPET. In PET imaging, no effect of
the drug was found on the distribution and accumulation of
64Cu-hJF5 in the lungs or other organs in infected animals, when
administered 24 h postinoculation. Even at 48 h postinoculation,
24 h after the drug was administered, no control of the disease
was evident. A possible explanation for this might be the biolo-
gical activity of VCZ, “holding” A. fumigatus46 infections by a
fungistatic effect until the immune system can take over. While
Fig. 5 ImmunoPET/MR evaluation of early- and late-stage voriconazole treatment on A. fumigatus lung infection. a Experimental workflow depicting
Aspergillus fumigatus (A.f.) infection, tracer injection, voriconazole administration (VCZ), and in vivo imaging using immunoPET/MR. b ImmunoPET/MR
images of A. fumigatus-infected animals receiving voriconazole (VCZ) treatment initiated 24 h post inoculation (p.i.) (A.f. VCZ (24 h), left, n= 6), or when
initiated at 3 h postinoculation and at 24 h p.i. (A.f. VCZ (3+ 24 h), right, n= 4). Images acquired 24 h p.i. are shown in the top row, while images in the
bottom row show images acquired 48 h p.i.. MIP is a maximum intensity projection of the PET image; MRI is a T2-weighted MRI single slice MRI image;
Fusion is a single slice PET image overlaid on the corresponding MRI slice. Magnifications of the fusion images of the lung are displayed below each image.
c Quantification of 64Cu-hJF5 accumulation in the lung tissue at 24 h (top) and 48 h (bottom) p.i. of A. fumigatus in animals left untreated (A. fumigatus,
red), receiving voriconazole treatment initiated 24 h after infection (A.f. VCZ (24 h), dark blue), or when initiated at 3 h postinfection and at 24 h
postinfection (A.f. VCZ (3+ 24 h), light blue). 48 h p.i.: A. fumigatus vs. A.f., VCZ (3 h+ 24 h), p= 0.0046; A.f., VCZ (24 h) vs. A.f., VCZ (3 h+ 24 h), p=
0.0025. d Percentage of lung volume occupied by thresholded PET signal at 24 h (left) and 48 h (right) postinfection in the same animals. At 24 h, 10%: A.
fumigatus vs. A.f., VCZ (3 h+ 24 h), p= 0.0023; A.f., VCZ (24 h) vs. A.f., VCZ (3 h+ 24 h), p= 0.0063. At 48 h, 10%: A. fumigatus vs. A.f., VCZ (3 h+ 24
h), p < 0.0001; A.f., VCZ (24 h) vs. A.f., VCZ (3 h+ 24 h), p < 0.0001 and 15%: A. fumigatus vs. A.f., VCZ (3 h+ 24 h), p= 0.0321; A.f., VCZ (24 h) vs. A.f.,
VCZ (3 h+ 24 h), p= 0.0009. Results are plotted as individual values with average and standard deviation and are expressed as percent injected dose per
cubic centimeter (%ID/cc) for PET. p values were generated using one way ANOVA (c) or two way ANOVA (d) with Tukey’s multiple comparison test
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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the effect of VCZ in limited time frames is, to the best of our
knowledge, undocumented in vivo, its initial activity in vitro is
likely to be fungistatic, with fungicidal activity following 24–48 h
earliest after initial fungal exposure47–49. Data from LSFM of the
lungs confirmed the immunoPET data, and similarly showed a
lack of reduction in IPA following late-stage administration of
VCZ. Our data showed that, in order to be effective, VCZ must be
administered as early as possible during the infection process in
the setting of neutropenia, with early/late-stage treatment pro-
viding complete remission of the disease. Our findings are con-
sistent with previous studies which have shown that early
intervention with antifungal drugs is critical to control of IPA38.
Our work has also demonstrated the power of JF5-guided ima-
ging as a means of tracking IPA in vivo during the course of
antifungal drug treatment. As a highly sensitive and disease-
specific tracer, and one that detects active growth of A.
fumigatus13,18–20, 64Cu-hJF5 represents a manifest improvement
over [18F]FDG-PET/CT32 as a means of discriminating
between invasive growth and resolution of infection. Accumula-
tion of the hJF5 tracer was similar in both treated and non-treated
animals, and correlated exclusively with the distribution of the
pathogen. This demonstrates the absence of false positive
accumulation (hJF5 accumulating in A. fumigatus-absent spaces)
and false negativity (hJF5 not accumulating in A. fumigatus-
rich spaces). In addition, the ex vivo results showed a
discrepancy between radiotracer uptake in the spleen of animals
infected with A. fumigatus compared to animals with a sham
inoculation. This might point toward dissemination of the
pathogen to the spleen, which has been reported several times in
humans50,51. However, it might alternatively demonstrate accre-
tion of soluble antigen released into the bloodstream during
invasion of the lung.
While the extended circulation time of full-length antibodies
(days to weeks) and their high bio-availability are a significant
advantage in many instances, these features do present an
important limitation for immunoPET in vivo, which is a high
blood pool of tracer. In our system, this typically manifested as
blood quantities of >20%ID/g in ex vivo biodistribution assays
and, more importantly, in vivo accumulation of 64Cu-hJF5 in the
highly perfused lungs of noninfected control animals. Biodis-
tribution studies showed a difference in blood circulation values
between infected (treated and non-treated) and control animals,
which we attribute to circulating antigen. We believe this PET
signal still originates from immunoreactive radiolabeled antibody,
as we have shown in previous studies the stability of 64Cu che-
lation to NODAGA-hJF5 as well as the conjugation between
NODAGA and hJF520. Since it is not possible to distinguish
blood vessels from lung tissue in immunoPET/MR, this translates
to a background signal that reduces the contrast between healthy
and diseased tissues in in vivo PET/MR. To mitigate this, we
conducted ex vivo measurements after thorough perfusion of the
animals with PBS in order to remove any unbound circulating
64Cu-hJF5 thereby allowing the distinction between circulating
radiotracer and bound immunoglobulin. The benefits of this
approach were clearly evident in LSFM, where control animals
showed no fluorescence signal at all due to 64Cu-hJF5-
DyLight650. Furthermore, the accumulation of 64Cu-hJF5
determined in ex vivo biodistribution assays was ~10-fold lower
in control animals compared to infected animals, and an
approximate 2-fold difference was achieved in in vivo PET at the
same time point. While this is a sizeable difference, it is very likely
a feature unique to the murine model of IPA since the lungs are
fully invaded by small nodules of fungus, which is apparent in the
LSFM images. This results in a dispersed mass at the resolution of
the PET system (~1 mm). This might lead to a partial volume
effect, ultimately lowering the estimated PET accumulation
values. In the case of a naturally infected human, IPA generally
presents as several compact nodules of a few centimeters against a
healthy tissue background52. Given the organ and nodule size in
relation to the conserved PET resolution, the contrast ratio
between positive nodules and healthy lung tissue should increase
considerably, and prove sufficiently different, for human disease
diagnosis and therapy monitoring. A possible means of reducing
the blood pool retention of the radiotracer, is to shorten the
circulation time of the targeting vector through chemical
manipulation. Antibody fragments are a classical approach, as
smaller fragments often conserve the affinity to the target of
interest but with a more limited circulation time, with typical
half-life times of 10 h for F(ab’)2 fragments or even less than 1 h
for nanobodies53. Such strategies are currently being investigated
by our group to achieve a higher contrast ratio between diseased
and healthy tissue at a faster rate than currently achievable with a
full-length radiolabeled antibody.
Notwithstanding this, and in order to achieve a higher contrast
ratio in vivo as well as better nodule delineation and disease sta-
ging, we developed a volumetric thresholding method applicable
to both LSFM and PET images. This allowed the values acquired
in vivo and ex vivo to be correlated, and provided a more robust
mechanism for disease detection. To achieve this, a delineation of
the organ was performed using a reference anatomical image
(MRI or autofluorescence for immunoPET and LSFM, respec-
tively), and the volume occupied by the specific signal above a
defined threshold value calculated. Initially, we used a threshold
value similar to that of the average background levels (5%ID/cc),
which yielded too much noise and variance to allow conclusive
results. While using a 10%ID/cc threshold provided more mean-
ingful results, the volumes occupied by the pathogen were largely
over-estimated when compared to the results obtained by LSFM.
This could be due to the high perfusion of the lung (and blood
containing ~20%ID/g), giving false positive signals indistinguish-
able from true nodule signals achievable at the resolution of small
animal PET. By increasing the threshold to 15%ID/cc, repre-
senting the maximal PET signal in healthy animal lungs, we were
able to obtain a clear delineation of the diseased regions of the
lungs, often matching with MRI T2 contrast, with values similar to
the LSFM values obtained ex vivo. Furthermore, we achieved a
significantly higher ratio between diseased and control lungs
in vivo than previously achieved using classical PET quantification
approaches. This effectively solved the main immunoPET issue of
high blood pool retention of mAb tracer.
In conclusion, we have shown that hJF5 can be used success-
fully in vivo as a diagnostic and therapy monitoring tool for IPA,
accurately tracking changes in pathogen load in the neutropenic
lung during disease progression and in response to antifungal
drug treatment. It is important to note that while this murine
model of IPA is an accurate representation of the clinical
aggressiveness of the pathogen in the context of immuno-sup-
pression, clinical presentation of IPA is typically as discrete
nodules rather than diffuse invasion of the contiguous lung. In
this event, the volumetric threshold procedure developed here
might prove useful for clinical diagnosis of the disease using
antibody-guided molecular imaging. We foresee that the main
applications of this immunoPET approach could be firstly to rule-
in or rule-out Aspergillus lung infection, and secondly to aid
identification of treatment end-point, improving clinical decisions
regarding duration of the antifungal therapy.
Methods
Preparation of labeled hJF5. For conjugation of hJF5 to NODAGA, purified hJF5
antibody was first incubated with EDTA (0.5 mM) for 45 min at room temperature
under gentle stirring to remove metal contamination. Buffer exchange and EDTA
excess removal was then performed using trace-metal basis 0.1 M boric acid
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(Sigma-Aldrich, Switzerland), pH 9.1, equilibrated with PD-10 (GE Healthcare,
Switzerland). Amicon Ultra-15 centrifugal filter units with a 10 kDa molecular
weight cut-off (Merck Millipore, Switzerland) were then used for antibody col-
lection. p-NCS-Bz-NODAGA (Chematech, France) was dissolved in DMSO at
33.3 mM and applied at a 20-fold molecular excess to the antibody solution
(33.3 µM) and the reaction took place for 16 h at 4 °C. After purification, per-
formed with a PD-10 column, the antibody was equilibrated in Chelex-treated PBS,
pH 7.4 (Bio-Rad, Switzerland). Filtration using Amicon Ultra-15 centrifugal filter
units (10 kDa cut off) and two further purification steps using Chelex-treated PBS
(pH 7.4) followed19.
For dual-labeled hJF5, the chelator-conjugated antibody was further conjugated
with a 10-fold molar excess of DyLight 650 NHS ester (Thermo Scientific,
Rockford, IL, USA) according to the manufacturer’s instructions. The conjugate
was purified using a PD-10 column equilibrated with phosphate-buffered saline.
The antibody was radiolabeled by incubation with 0.5 MBq 64Cu per µg for 60 min
at 42 °C.
64Cu was produced in house by 12.5 MeV proton irradiation of enriched 64Ni
metal electroplated on a platinum/iridium disc via the 64Ni(p,n)64Cu nuclear
reaction, and purified after acidic dissolution by anion exchange chromatography.
Antibodies coupled to NODAGA were then radiolabeled using 0.5 MBq of acetate-
buffered 64CuCl2 per µg of antibody.
Quality control was performed using thin layer chromatography (Polygram SIL
G/UV254, Macherey-Nagel; mobile phase: 0.1 M sodium citrate, pH 5.0) and
HPSEC (Phenomenex BioSep SEC-s3000 300 × 4.6 mm, 1.5 ml/min saline sodium
citrate). Reactivity of antibody conjugates was confirmed by ELISA with purified
antigen as described previously20.
Aspergillus fumigatus strains and voriconazole susceptibility testing. The
Aspergillus fumigatus wild-type strain ATCC 46645 and strain A. fumigatustdTomato
(strain ATCC 46645 with insertion of the tdTomato gene via pSK379-Tomato
plasmid in the His2 sequence54) were grown on defined minimal medium for three
days at 37 °C before resting conidia were harvested from sporulating mycelium
with tap water+ 0.1% Tween-20. The growth medium of the A. fumigatustdTomato
strain was supplemented with 0.1 µg/ml pyrithiamine hydrobromide (Sigma-
Aldrich, St. Louis, Missouri, USA) as selection marker. Spore suspensions were
filtered through a series of cell strainers with decreasing mesh size (100, 30, and 10
µm) before spore concentration was assessed using an automated cell counting
system (Cellometer Auto T4; Nexcelcom, Manchester, UK). After adjusting the
spore concentration to 3 × 105 spores/ml with deionized water, 100 µl of these
suspensions were used per well to inoculate the EUCAST 96-well flat-bottom
testing plates (TPP, Trasadingen, Switzerland). Previously, these standard cell
culture plates were filled with 100 µl double-concentrated EUCAST medium
(RPMI 1640 (with glutamine and a pH indicator but without bicarbonate)+ [4%]
(w/v) Glucose+ [0.33 mol/l] 3-(N-morpholino) propanesulfonic acid (MOPS)) per
well with which double-concentrated dilution series of voriconazole (Vfend; Pfizer,
New York City, USA; reconstituted with sterile, deionized water) were generated
(32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06 µg/ml). By adding 100 µl of the spore
suspensions to the wells of the 96-well plates the total spore number per well
equated to 3 × 104, the EUCAST medium was diluted to become 1× concentrated
(RPMI 1640+ [2%] Glucose+ [0.165 mol/l] MOPS), and the final voriconazole
concentrations were adjusted to 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03 µg/ml. For
each strain, two individual spore preparations were used (=biological replicates)
from which three separate voriconazole dilution series were inoculated (=technical
replicates). The inoculated plates were then incubated for 48 h at 37 °C before the
MIC values were determined. For visual MIC determination, all inoculated testing
rows were investigated with a stereo microscope (S8 APO; Leica Microsystems,
Wetzlar, Germany) for the first well of the row in which no fungal growth was
detectable. Subsequently, for assessing the MIC values spectrophotometrically, the
absorbance at 490 nm of all inoculated wells of the 96-well plates was measured
(iMark; Biorad, Hercules, California, USA). As blank control, fresh 1× con-
centrated EUCAST medium was used.
Mouse strain. For all experiments, C57BL/6JOlaHsd mice were used. Eight to ten-
week-old female mice were purchased from Envigo (Huntingdon, Cambridgeshire,
UK), and kept in a standardized and sterile environment (20 ± 1 °C room tem-
perature, 50 ± 10% relative humidity, 12 h light–dark cycle), with food and water
provided ad libitum. All experiments were undertaken in accordance to the animal
welfare act and the EU directive 2010/63/EU, the German animal welfare act and
after review and approval by the responsible local ethical committees and autho-
rities (Regierungspräsidium Tübingen and Essen, Germany).
A. fumigatus infection and treatment. Mice were rendered neutropenic by an
intraperitoneal (i.p.) injection of 100–200 µg anti-Ly6G/anti-Ly6c antibody
(BioXCell, West Lebanon, USA) diluted to 1 mg/ml in PBS (DPBS, Gibco Life
technologies, Carlsbad, CA, USA) 18–24 h prior to fungal infection or injected by
an equivalent amount of isotype antibody for the isotype-depleted group. For the
infection procedure, mice were first anaesthetized with 100 µl of Ketamin/Xylazin
or Rompun solution i.p. (Ketamin: 80–100 mg/kg. Ratiopharm GmbH, Ulm;
Rompun: 15 mg/kg. Bayer HeathCare, Leverkusen or Xylazin 2%: 10 mg/kg. WDT,
Garbsen), before intubation using a 22-gauge in-dwelling venous catheter (Vasofix
Braunüle, B. Braun AG, Melsungen, Germany). Correct intubation in the trachea
was confirmed by ventilation, before deposition of a suspension of 4–5 × 106 spores
of A. fumigatus in 50–100 µl PBS (MiniVent, Hugo Sachs, March-Hugstetten,
Germany). Either wild-type A. fumigatus or A. fumigatustdTomato were used
depending on the experiment. Complete distribution in the lungs was obtained by
artificial ventilation (250–300 µl/breath at 200–250 breaths/min for 1 min using a
small animal respirator). Control animals received an equal volume of the PBS
carrier only.
For immunoPET/MRI experiments, mice were then randomly split into groups,
and received the following treatments: (1) no antifungal treatment (A. fumigatus
only group); (2) a single i.v. injection of 6 mg/kg of VCZ (Hexal, Holzkirchen,
Germany) 24 h after infection (late-stage VCZ treatment); (3) an i.v. injection of 6
mg/kg of VCZ 3 h after infection, followed by a second injection of 4 mg/kg of VCZ
24 h after infection (early/late-stage VCZ treatment).
Immediately after infection, mice were separated by experimental groups to
avoid cross contamination, in litters of maximum 6 littermates. Thus, no blinding
of the investigator was possible.
In vivo immunoPET/MR imaging. Directly after intratracheal infection of the
animals, ~12.5 MBq of radiolabeled hJF5, corresponding to ~25 µg of protein
(64Cu-hJF5 injected 3.04 mg/ml, 64Cu-hJF5-DyLight650 at 1.25 mg/ml) at, was
injected i.v. In vivo imaging took place 24 and 48 h after initial infection of the
animals using a small animal PET system (Inveon™, Siemens Healthcare GmbH,
Erlangen, Germany), using the Inveon Acquisition Workplace (IAW)
v2.1.272 software (Siemens Preclinical Solutions, Knoxville, TN, USA) thoroughly
calibrated55 and undergoing daily quality and linearity response controls, ensuring
reproducibility of measurements, and a small animal MRI using the Paravision
v6 software (7 T Bruker Biospin GmbH, Billerica, MA, USA). Before each imaging
session, the animals were weighed and their appearance was checked for physical
or behavioral abnormalities. During the scans, the animals were anaesthetized with
0.8–2.5% isoflurane in 100% oxygen (depending on their health and fitness).
Anesthesia was monitored by measuring the breathing frequency. Mice were
positioned into a PET and MRI transparent animal holder alongside two capillaries
containing a minimal amount of radioactivity for coregistration of PET and MRI
imaging data. For acquisition, a 600 s static PET acquisition sequence was used
followed by two MRI sequences (T2_TurboRARE (TR/TE 600 ms/35 ms, size
256 × 128 × 92 mm, slice thickness 23 mm, field of view (FOV) 64 × 32 × 12 mm,
and resolution 0.25 × 0.25 × 0.25) and T1-FLASH (TR/TE 12/3 ms, FA 8.9°, size
160 × 80 × 60 mm, slice thickness 18.868 mm, FOV 50 × 25 × 18.868 mm, and
resolution 0.314 × 0.314 × 0.314)). PET image reconstruction was performed using
a 3D ordered subset expectation maximization (3D-OSEM) with no attenuation
correction in IAW and co-registered with MRI images using in Inveon Research
Workplace software v4.2 (Siemens Preclinical Solutions, Knoxville, TN, USA).
Region of interest (ROI) was drawn onto the lungs using the MR Images for
guidance, and the PET data were used to extract percent injected dose per cubic
centimeter (cc) [%ID/cc] in the lung. Lung volumes were measured using the ROI
as delineated in the MRI, or measured based on the PET data after thresholding the
initial lung ROI at a defined %ID/cc value.
Ex vivo analysis. After the last in vivo imaging scans, retro-bulbar blood samples
were obtained from the animals before CO2 sacrifice. Shortly thereafter, all animals
were perfused through the left ventricle with 0.4% of PFA (Sigma-Aldrich,
Darmstadt, Germany) in 20 ml of 4 °C PBS. Afterwards, organs were removed and
radioactivity was quantified with an aliquot of the injected radiotracer in a
γ-counter (Wallac 2480 WIZARD 3″, PerkinElmer, Waltham, MA, USA) using an
energy window between 350 and 650 keV. The results are expressed as % injected
dose per gram (%ID/g) of tissue.
CUBIC clearing and 3D fluorescence microscopy. Organs prepared for 3D
fluorescence microscopy were cleared with the CUBIC protocol as previously
described56. All incubation steps were performed in the dark. Fixated lungs were
transferred to 0.01% NaN3/PBS (Sigma-Aldrich, Darmstadt, Germany) overnight
at RT with shaking. After an additional washing step with 0.01% NaN3/PBS, the
lungs were incubated in 50% CUBIC reagent-1/dH2O and 3 h at RT with shaking.
Reagent-1 was prepared according to the published protocol56 and was comprised
of 25% Urea (Sigma-Aldrich, Darmstadt, Germany), 25% Quadrol (Sigma-Aldrich,
Darmstadt, Germany) and 15% Triton X-100 (Sigma-Aldrich, Darmstadt, Ger-
many) in dH2O. On the next day, the samples were transferred in 100% reagent-1
over night at RT with continuous shaking, followed by replacement of the solvent
by fresh reagent-1 on the next day for an additional 24 h period incubation. Fol-
lowing the incubation period, 3 × 2 h washing cycles at RT with 0.01% NaN3/PBS
were performed with shaking and the lungs immediately immersed in 50% CUBIC
reagent-1/PBS over night at RT. Reagent-2 was prepared following the established
protocol56 with 25% urea, 50% sucrose (Sigma-Aldrich), and 10% triethanolamine
(Sigma-Aldrich) in dH2O. Final clearing was performed in pure reagent-2 over-
night at RT with gentle shaking, followed by a last change of reagent-2 for at least
24 h at RT, with shaking. Before image acquisition, samples were preincubated in a
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mixture of 50% silicon oil (Sigma-Aldrich) and 50% mineral oil (Sigma-Aldrich)
30 min, before imaging in the same oil composition.
All samples were imaged using an Ultramicroscope II and ImSpector software
(LaVision BioTec, Bielefeld, Germany). The microscope is based on a MVX10
zoom body (Olympus, Hamburg, Deutschland) with a ×2 dipping objective, and
equipped with a Neo sCMOS camera (Andor, Oxford instruments, Tubney Woods,
Abingdon, UK). Samples were imaged along the coronal axis in a commercially
available sample holder and cuvette (LaVision BioTec), with a total magnification
of ×1.26 or ×4 and a z spacing of 10 or 5 µm between optical planes. A FOV with
2560 × 2160 pixel and a diagonal of 17.6 or 5.5 mm resulted in a x/y pixel size of
5.16 or 1.62 µm. For image acquisition, samples were excited with light sheets of the
wavelengths 488, 561, and 639 nm. The longest wavelength was imaged first and
shortest last to avoid photobleaching during imaging. A bandpass emission filter
with a center wavelength of 525 nm and a bandpass width of 50 nm (525/50) was
used for the detection of autofluorescence, 585/40 for the detection of the
tdTomato signal of A. fumigatus and 680/30 for the DyLight650 signal of the hJF5
antibody.
Multiphoton images of fungal development were generated from the right
inferior lobes using the Leica TCS SP8 MP and Leica Application Suite (LAS X)
software (Version 3.1.5.16308; Leica Microsystems GmbH, Wetzlar, Germany). Z-
stacks of 150 µm with a spacing of 0.5 µm were acquired using the 2.8W
Chameleon Vision II Titan-Sapphire laser with an excitation wavelength of 960
nm. A ×25 objective (Leica Microsystems GmbH) with a ×1.5 zoom and a scan
speed of 100 Hz resulted in a FOV with the size of 295.24 µm × 295.24 µm in
1024 × 1024 pixels, and a x/y pixel size of 0.289 µm. Autofluorescence was detected
with a photomultiplier tube (PMT) bandpass emission filter 525/50, and tdTomato
signal with a hybrid detector (HyD) 585/40.
Confocal images of the whole lungs, first imaged using PET/MRI, were acquired
using the Leica TCS SP8 gSTED equipped with a 1.5 mW tuneable white light laser
and LAS X software (Version 3.5.5.19976; Leica Microsystems GmbH). With a ×20
objective (Leica Microsystems GmbH), excitation wavelengths of 488 nm (52%),
554 nm (63%), 652 nm (63%) and a scan speed of 400 Hz, z-stacks of around 200
µm with a spacing of 1 µm were acquired. A FOV with the size of 581.25 µm ×
581.25 µm (2048 × 20,148 pixels) results in a x/y pixel size of 0.284 µm.
Autofluorescence was detected with a tuneable PMT of 499–525 nm, tdTomato
signal with a tuneable HyD of 561–626 nm, and DyLight650 with an HyD of
670–718 nm.
Image processing. Recorded z-stacks (16 bit OME.TIF) were converted into
Imaris files (.ims (Bitplane AG, Oxford instruments, Zurich, Switzerland)) using
the ImarisFileConverterx64 (Version 9.4.X and 9.5.X). The 3D reconstruction of
the surfaces, and the subsequent analyses, were performed with Imaris (Version
9.5.X, Bitplane). The displayed surface of A. fumigatustdTomato signal was built
using a threshold from 1000 to 3969.38 counts, and the displayed surface of hJF5-
DyLight650 signal with 500 to 1117.71 counts. For the co-localization of both
signals, we reconstructed a new surface from the A. fumigatus surface with the
threshold values from the hJF5 surface reconstruction and calculated the overlap.
Histology. After sacrifice, animals were perfused with 20 ml PBS at 4 °C before
organ removal. Whole lungs were fixed in 4% formalin and paraffin embedded.
Tissue sections of 3–5 µm thick were prepared and stained with H&E and Grocott
to demonstrate fungal structures. Appropriate positive and negative controls were
used to confirm the adequacy of the staining. Photomicrographic images were
acquired with an Axioskop 2 plus Zeiss microscope equipped with a Jenoptik
(Laser Optik System, Jena, Germany) ProgRes C10 plus camera and software. Final
image preparation was performed with Adobe Photoshop CS6.
Statistical analysis. Sample sizes were chosen based on previously published
studies using similar conditions20. Infected animals were removed from the study
based on previously established criteria of weight loss, which had to be between 5%
and 20% between the day of infection and the 48 h timepoint, indicating a failed
infection or requiring ethical sacrifice, respectively. Statistical analysis was per-
formed using GraphPad Prism 9.0.0 for Windows (GraphPad Software, San Diego,
CA, USA). Given data are indicated in the figure legends. Specific tests to deter-
mine statistical significance are noted in each sure legend. Correlation was acquired
with linear regression best-fit, and the Pearson’s correlation coefficient r was cal-
culated. p values are depicted, with a value of p < 0.05 considered significant.
Collected PET and Biodistribution data passed the Shapiro–Wilk’s normality test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Due to their large size, the raw imaging data that support the findings of this study are
directly available from the corresponding authors upon reasonable request. Derived data
have been compiled in the Source Data file provided with this paper. Any remaining data
supporting the findings from this study are available from the corresponding author
upon reasonable request.
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